Friedrich & ClementBETA

DAK-Gesundheit

Germany · 645 open tenders · 4,749 documented awards

Current tenders

Software for Hospital Invoice Verification
Deadline 12 Oct ·
Software for Hospital Invoice Auditing
Deadline 12 Oct ·
Nationwide supply and assembly of furnishings for "Get2Gether rooms" in DAK-Gesundheit service locations
Deadline 19 Oct ·
Event logistics nationwide
Deadline 19 Oct ·
Event logistics nationwide
Deadline 19 Oct ·
Nationwide supply and installation of furnishings for "Get2Gether rooms" in the DAK-Gesundheit service centers
Deadline 19 Oct ·
Procurement of an App for Training Cognition and Language in Neurological Diseases
Deadline 26 Oct ·
Procurement of an App for Training Cognition and Language in Neurological Diseases
Deadline 29 Oct ·
Procurement of an App for Training Cognition and Language in Neurological Diseases
Deadline 29 Oct ·
Lecture and seminar for executives and staff representatives, lecture and seminar for employees
Deadline 30 Oct ·
BGM substance abuse prevention
Deadline 30 Oct ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active substance Apremilast, (OBO) ATC L04AA32 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for the active ingredient Ginkgo biloba leaf dry extract, (OBG) ATC N06DP01 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for the active ingredient sevelamer hydrochloride, (OBG) ATC V03AE02 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Rotigotine, (OBG) ATC N04BC09 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Clindamycin + Benzoylperoxid, (OBG) ATC D10AF54 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a (8) SGB V for the active ingredient allergen extract from tree pollen (excl. in the form of pump solution), ATC V01AA05 for the period 01.01.25 - 31.12.26
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient teriflunomide, ATC L04AK02 for the period 01.10.2025 - 31.12.2025 (plus extension option 1x12 months)
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient sevelamer hydrochloride, (OBG) ATC V03AE02 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a Para. 8 SGB V for the active substance allergen extract from tree pollen (excl. in the form of pump solution), ATC V01AA05 for the period 01.01.25 - 31.12.26
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement according to § 130a para. 8 SGB V for the active ingredient dexamethasone (excluding implant), (OBG) ATC S01BA01 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Clindamycin + Benzoylperoxide, (OBG) ATC D10AF54 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a para. 8 SGB V for the active ingredient Pyridostigmine (excluding extended-release Dafo.), (OBG) ATC N07AA02 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Rotigotine, (OBG) ATC N04BC09 for the period 01.01.2025 - 31.12.2026
Deadline 5 Nov ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a (8) SGB V for the active ingredient perindopril and indapamide (excluding perindopril as arginine salt), ATC C09BA54 for the period 01.02.25 - 31.01.27
Deadline 4 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a Abs. 8 SGB V for the active ingredient Aripiprazole (excl. Dafo for the manufacture of a DIS), (OBO) ATC N05AX12 for the period 01.02.2025 - 31.01.2027
Deadline 4 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a (8) SGB V for the active ingredient flupentixol, (OBG) ATC N05AF01 for the period 01.02.2025 - 31.01.2027
Deadline 4 Dec ·
Conclusion of a non-exclusive rebate agreement pursuant to § 130a Abs. 8 SGB V for the active ingredient PEG-Epoetin beta, (OBO) ATC B03XA03 for the period 01.02.2025 - 31.01.2027
Deadline 4 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a (8) SGB V for the active ingredient Baricitinib, (OBO) ATC L04AA37 for the period 01.02.2025 - 31.01.2027
Deadline 4 Dec ·
Conclusion of a non-exclusive discount agreement pursuant to § 130a para. 8 SGB V for the active ingredient Lipegfilgrastim, (OBO) ATC L03AA14 for the period 01.02.2025 - 31.01.2027
Deadline 4 Dec ·

Purchasing rhythm

Awards per year — who knows the rhythm prepares before the notice appears.

2018197
2019242
2020202
2021244
2022266
2023372
2024891
20251,337
2026789

Clement What the numbers say about this buyer

  • The median procedure drew 9 bids (3,316 procedures with a bid count); 7% ended with a single bidder. Country: median 3.1 bids.n = 3,316
  • 81% of this buyer's awards went to companies that had already won here before (3,321 awards since 2017, spread over 567 companies). That is well above the national norm (45%) — newcomers have a harder time here than elsewhere.n = 3,321 awards since 2017
  • The award came in at a median 79% of the estimated value (6 awards with both estimate and value) — pricing at the estimate is usually too high here. Country: 86%.n = 6
  • Across 261 procedures with structured selection criteria, this buyer most often required: Staff qualifications (253 of 261), Professional liability insurance (11 of 261), References: services (6 of 261), Minimum annual turnover (5 of 261).n = 261
  • From notice to award takes a median 47 days here (599 procedures). Country: 91 days.n = 599
  • 83% of the bids received came from small and medium-sized enterprises (15 procedures with a bid mix). Country: 75%.n = 15
  • 2% of awards went to companies from abroad (3,321 awards with a known winner country). National average: 1%.n = 3,321

From this buyer's documented awards; comparison values from the same sector and country. Not a forecast, not legal advice. As of 04/10/2026.

Expected next awards

From the rhythm of past awards per sector — an expectation, not an announcement. Hit rate so far: 26% of 11,200 closed expectation windows produced a notice.

Who has won here before

CompanyAwardsPeriod
Abacus Medicine A/S · Kopenhagen1882022–2026
kohlpharma GmbH · Merzig1722022–2026
EurimPharm Arzneimittel GmbH · Saaldorf-Surheim1372022–2026
CC Pharma GmbH · Densborn1332022–2025
Orifarm GmbH · Leverkusen1252015–2026
axicorp Pharma B.V. · EC Den Haag922022–2025
Originalis B.V. · Amsterdam832022–2025
ratiopharm GmbH802015–2026
Zentiva Pharma GmbH · Frankfurt am Main592015–2026
Hexal AG · Holzkirchen582013–2025

From 18.0M documented awards · regular winners know this buyer's requirements — that is your competition.